Core Points - Zhifei Biological's subsidiary, Beijing Zhifei Lvzhu, has received the clinical trial application acceptance notice from the National Medical Products Administration for its self-developed acellular pertussis-diphtheria-tetanus (Tdap) combined vaccine for adults and adolescents, marking a significant breakthrough in the multi-valent vaccine development field [1] Group 1 - The vaccine aims to fill the market gap for adult and adolescent booster immunization against pertussis, diphtheria, and tetanus in China [1]